Merck & Co., Inc. (NYSE: MRK) reported Q1 EPS of $0.88, $0.09 better than the analyst estimate of $0.79. Revenue for the quarter came in at $10.3 billion versus the consensus estimate of $10.44 billion. Merck & Co., Inc. (NYSE:MRK) shares after opening at $57.50 moved to $58.86 on last trade day and at the end of the day closed at $58.72. Company price to sales ratio in past twelve months was calculated as 3.92 and price to cash ratio as 9.87. Merck & Co., Inc. (NYSE:MRK) showed a positive weekly performance of 1.64%.
New Brunswick, New Jersey, US: American pharmaceutical giant Johnson & Johnson (NYSE:JNJ) has suspended sales of the devices used in fibroid surgery amid concerns about their potential to spread a rare but deadly cancer, reported The Wall Street Journal. Johnson & Johnson (NYSE:JNJ) shares fell -0.31% in last trading session and ended the day on $101.03. JNJ return on equity ratio is recorded as 21.50% and its return on assets is 11.90%. Johnson & Johnson (NYSE:JNJ)yearly performance is 21.55%.
Allergan, Inc. (NYSE:AGN) has contacted companies including Sanofi and Johnson & Johnson to see if either would be interested in acquiring the Botox maker, said people with knowledge of the matter, as it explores its options after receiving an unsolicited $45.7 billion bid from Valeant Pharmaceuticals Inc. Allergan, Inc. (NYSE:AGN) shares moved down -0.22% in last trading session and was closed at $165.63, while trading in range of $164.85-$169.29. Allergan, Inc. (NYSE:AGN) year to date performance is 49.16%.
Hospira (NYSE: HSP), the world’s leading provider of injectable drugs and infusion technologies, last week shared results from a post-authorization observational safety study, conducted in clinical sites in Europe, of biosimilar epoetin product Retacrit™/Silapo® (epoetin zeta) in patients with renal anaemia. The study’s results, presented at the National Kidney Foundation 2014 Spring Clinical Meetings, exhibited a safety pattern for Retacrit/Silapo comparable with known data for other epoetin alfa products. Retacrit is marketed in Europe by Hospira, and Silapo is marketed in Germany by cell pharm GmbH, a 100% subsidiary of STADA Arzneimittel AG. Retacrit and Silapo are manufactured by STADA Arzneimittel AG. Hospira, Inc. (NYSE:HSP) weekly performance is 4.00%. On last trading day company shares ended up $45.46. Hospira, Inc. (NYSE:HSP) distance from 50-day simple moving average is 5.64%. Analysts mean target price for the company is $42.09.
Leave a Reply